Answers are grounded in this paper and cite their sources.
Drug-resistant epilepsy (DRE) remains a formidable clinical challenge, affecting nearly 30-40% of patients despite optimized pharmacotherapy. In patients for whom resective surgery is contraindicated or poses unacceptable risks, neuromodulatory therapies-most notably deep brain stimulation (DBS)-have emerged as viable and reversible treatment options. This narrative review critically examines the current applications of DBS for DRE, with a focus on major targets including the anterior thalamic nucleus, centromedian nucleus, hippocampus, and emerging targets such as the pulvinar. We provide an in-depth discussion of the therapeutic mechanisms underlying DBS-from local cellular inhibition and desynchronization to widespread network modulation and neuroplasticity induction-and review the latest advances in sensing technologies, patient-specific connectivity mapping, and closed loop stimulation paradigms. In addition to integrating data from randomized controlled trials, long-term observational studies, and advanced imaging investigations, we discuss limitations, persistent challenges, and future research directions that will guide clinical decision-making and optimize therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Shon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: